Fresenius: 74% of U.S. HvHDF Treatments Hit Dose Target
Bad Homburg, Germany – October 19, 2026 -- Fresenius Medical Care reports that 74% of more than 10,000 high-volume hemodiafiltration (HvHDF) treatments delivered on its 5008X CAREsystem in the United States reached the target convective dose of 23 liters or greater. The company will present the data at the American Society of Nephrology's Kidney Week 2026, held October 21-25 in Denver, Colorado.
U.S. real-world data shows HvHDF delivery matches European targets
The company says the findings show HvHDF can be delivered in routine U.S. clinical practice with treatment targets comparable to those reported in Europe. Fresenius researchers are studying U.S. implementation as adoption expands. The work feeds the company's BEACON-US research initiative, which examines online HDF therapy and patient outcomes in the U.S.